. Author manuscript; available in PMC: 2020 Mar 30.

Published in final edited form as: Biomed Pharmacother. 2019 Aug 7;118:109323. doi: 10.1016/j.biopha.2019.109323

Table 4.

Evaluation of electrocardiographic parameters of 4T1 breast tumor-bearing female BALB/c mice treated with DOX, SpHL-DOX, or SpHL-DOX-Fol. Each treatment was intravenously administered 4 times, every 3 days, at a dose of 5 mg/kg.

Parameter	Dose	DOX	SpHL-DOX	SpHL-DOX-Fol
Heart Rate (beat/min)	Baseline	475 ± 59	411 ± 71	438 ± 29
Heart Rate (beat/min)	After Dose 4	433 ± 54	470 ± 61	457 ± 28
PR Interval (ms)	Baseline	32 ± 4	35 ± 5	34 ± 8
PR Interval (ms)	After Dose 4	33 ± 4	33 ± 3	32 ± 4
QRS Complex (ms)	Baseline	40 ± 7	41 ± 4	44 ± 4
QRS Complex (ms)	After Dose 4	48 ± 8	47 ± 7	50 ± 5

Data are expressed by the mean ± standard deviation of the mean (n = 5). All data were analyzed by one-way ANOVA analysis of variance followed by Tukey’s post-test.